Anti-CD73 Antibody Variants for Enzyme Blocking and Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for the development of effective, safe, and potent antibody agents directed against CD73, as current research has not adequately addressed the immunosuppressive role of CD73 in cancer and its impact on tumor microenvironments, despite advances in targeting this protein for clinical benefit.
Innovation Solution
Development of anti-CD73 antibodies, variants, and antigen binding fragments that specifically bind to CD73, inhibit its enzymatic activity, and induce intracellular internalization, which can be used alone or in combination with other agents to treat cancers associated with CD73 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used to target CD73, then the treatment can be administered, but the efficacy and safety are limited
Solution Approach 1:
The patent introduces multiple parameter changes in the antibody structure including amino acid substitutions at specific positions (e.g., L235E, P331S, L234F mutations in the Fc region), glycosylation modifications (N297Q mutation), and Fc region engineering to alter binding affinity, effector function, and pharmacokinetic properties. These parameter changes resolve the contradiction by enhancing anti-tumor efficacy through improved CD73 binding and macrophage activation while maintaining safety through controlled immunogenicity and reduced off-target effects.
2Reliability
If antibody structure is modified to enhance anti-tumor activity, then efficacy improves, but complexity of development increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional modules: the variable region for CD73 binding, the Fc region for effector function, and specific engineered domains for enhanced stability. By segmenting the antibody structure and optimizing each region independently (e.g., separate engineering of CDRs for affinity and Fc region for effector function), the patent achieves enhanced anti-tumor activity while managing development complexity through modular design.
Solution Approach 2:
The patent creates multi-functional antibodies that simultaneously perform multiple functions: CD73 binding inhibition, macrophage activation via Fc receptor engagement, and enhanced serum half-life through FcRn binding. The engineered antibodies (e.g., HLX01, N1, N4 variants) exhibit universal applicability across different cancer types expressing CD73, resolving the contradiction by achieving broad anti-tumor activity through multi-functionality while using standardized engineering approaches that manage complexity.
3Reliability
If CD73 enzymatic activity is inhibited, then adenosine signaling is blocked and immunotherapy is enhanced, but tumor microenvironment complexity increases
Solution Approach 1:
The patent uses the engineered anti-CD73 antibodies as intermediaries that bridge the gap between CD73 inhibition and immune system activation. The antibodies bind to CD73 on tumor cells and simultaneously engage Fc receptors on macrophages, serving as a mediator that translates enzymatic inhibition into enhanced anti-tumor immunity. This intermediary approach resolves the contradiction by enhancing immunotherapy through controlled mediation of the tumor microenvironment rather than direct complex interactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies demonstrate improved anti-tumor activities by enhancing immune responses and inhibiting tumor growth, particularly in human cancer models, including melanoma, head and neck cancer, and breast cancer, through macrophage-mediated phagocytosis and enzymatic inhibition.
Implementation Method 1
anti-CD73 antibodies and their affinity variants and/or mutants or antigen binding fragments can be used for detecting CD73 protein in patients
Implementation Method 2
CD73 hydrolyzes adenosine monophosphate (AMP), a product from adenosine triphosphate (ATP) hydrolysis pathway by CD39, to adenosine
Implementation Method 3
CD73 hydrolyzes adenosine monophosphate (AMP)
Implementation Method 4
enhanced macrophage-mediated phagocytosis
Data Source
AI summary
Provided are anti-CD73 antibodies, variants, and antigen binding fragments thereof. The antibodies, the variants, and the antigen binding fragments thereof bind to human CD73 with high affinity, and suppress the enzymatic activity of CD73, and optionally induce CD73 internalization. Further provided are isolated nucleic acid molecules encoding the anti-CD73 antibodies, the variants, and the antigen binding fragments thereof, and a related expression vector and a host cell. Provided is a method for preparing the anti-CD73 antibodies, the variants, and the antigen binding fragments thereof. Further provided are related pharmaceutical compositions and a method for using said pharmaceutical compositions in treating a subject.